BSE: 544738
SPECIALITY MEDICINES LIMITED
Markets and distributes finished pharmaceutical formulations in India as its single reportable segment, with FY2026 revenue from operations of Rs 7,528.51 lakh, up 29.2% from Rs 5,827.14 lakh in FY2025, and net profit of Rs 1,303.29 lakh. The company recently listed on BSE on March 30, 2026 under scrip code 544738 following an IPO completed in March 2026. Total equity capital stands at Rs 8.78 crore across 87,85,796 shares of Rs 10 each. Disclosed operating costs comprise employee cost at 2.3% of revenue and other operating expenses at 7.6% of revenue, with capex of Rs 0.008 crore in FY26. The company holds startup recognition under Section 80-IAC of the Income Tax Act, providing tax benefits. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Marketing and distribution of finished pharmaceutical formulations. Asset-light pharmaceutical marketing and distribution
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY26 |
|---|---|
| Revenue | 75 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 20.11 |
| ROE % · ROCE % | — · 18.8 |
| Debt / equity (x) | — |
| Cash from operations | (1) |
| Capex | (0) |
Exhibit 2: Quarterly performance, last 1 quarters
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 45 |
| Profit before tax | 8 |
| Net profit | — |
| EPS (₹) | 12.54 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 11.3 | 30.1 | 26 of 158 | 84% |
| ROCE | 17.0 | 10.8 | 48 of 183 | 74% |
| Market cap | 124 | 810 | 127 of 181 | 30% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 15 Oct 2026 · Compliance certificate under SEBI Regulation 74(5) for Sep 2026 quarter | compliance | minimal | — | — |
| 28 Sept 2026 · Insider trading window closed ahead of H2 FY26 results | compliance | minimal | — | — |
| 28 Sept 2026 · 5th AGM results: both resolutions passed with 100% approval | board shareholder meetings | low | — | — |
| 28 Sept 2026 · 5th AGM held via video conferencing; FY26 PAT up 81% YoY | board shareholder meetings | low | — | — |
| 5 Sept 2026 · AGM notice published in newspapers, meeting on 28 Sep 2026 | compliance | minimal | — | — |
| 3 Sept 2026 · Annual Report FY 2025-26 submitted to BSE | results | high | — | — |
| 3 Sept 2026 · Notice of 5th AGM on September 28, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Board approves FY26 Directors Report and sets 5th AGM for Sept 28, 2026 | board shareholder meetings | low | — | — |
| 12 Aug 2026 · Speciality Medicines gets approval for 2 new products in Ethiopia | business updates | medium | — | — |
| 12 Aug 2026 · Speciality Medicines gets Ethiopia approval for two new products | compliance | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.